Скачать или смотреть Canada Approves a New Pill for Postpartum Depression (But There’s a Catch)

Canada has approved a new oral treatment for postpartum depression that promises relief in just 14 days — with some patients improving as early as day three.

On paper, it sounds like a breakthrough.

But when you look closer, three major issues emerge:
• Limited long-term clinical data
• Real-world access barriers for prescribers
• And a price tag that raises serious equity concerns

In this video, we break down how this drug works, why it’s being compared to a $34,000 IV infusion, and the uncomfortable question no one seems willing to ask:

Is this real progress — or just another treatment only a few can afford?

This is not medical advice. This is a discussion about drug development, regulation, access, and healthcare reality.

👇 Leave a comment:
Should this medication be covered by public insurance?
#PostpartumDepression
#HealthcareAccess
#PharmaIndustry
#DrugDevelopment
#MentalHealth
#CanadianHealthcare
#Biotech
#HealthPolicy
#MedicalInnovation
#PublicHealth